Opening an infusion center involves navigating a dense mix of real estate, clinical licensing, pharmacy regulations, payer contracts, and staffing decisions, all before seeing your first patient. The financial opportunity is real: health plans recognize that ambulatory infusion is far cheaper than hospital-based infusion, and the market for infused therapies continues to grow as more biologics and immunotherapies reach the market. But the startup risks are steep enough that physician groups and entrepreneurs need to understand the full picture before committing capital. What follows covers the practical decisions you will face, roughly in the order you will face them.
Choosing a Business Model
Before you design a floor plan or hire a nurse, you need to decide what kind of infusion center you are building. The three most common structures are physician-owned office-based centers, hospital outpatient departments (HOPDs), and independent freestanding infusion centers. Each carries different reimbursement rates, regulatory requirements, and overhead profiles. Up to 60% of Medicare Part B cancer drug and radiotherapy services are delivered in hospital outpatient settings, with the remaining 40% occurring in freestanding physician office settings.1PubMed Central. Supervision Requirements in the 2020 Hospital Outpatient Prospective Payment System: Implications for Cancer Care in the United States That split matters because reimbursement under the Hospital Outpatient Prospective Payment System tends to be higher than what the Physician Fee Schedule pays freestanding sites for the same drugs and services.
A physician group that already manages patients on infused therapies might see an in-house center as a way to keep revenue within the practice rather than sending patients to a hospital. Health plans generally support this shift toward ambulatory settings because the cost savings are substantial compared to hospital administration fees.2PubMed Central. Build your own infusion clinic But that same article cautions physician groups to weigh the steep risks before jumping in. Drug acquisition costs are high, reimbursement can be slow or denied, and one bad payer contract can wipe out margins. Independent entrepreneurs who are not themselves clinicians face additional complexity around physician supervision rules and clinical liability.
Estimating Startup Costs
There is no single reliable published figure for the total cost of opening an infusion center, because it depends heavily on your model, your geography, and how many chairs you plan to operate. That said, the major cost buckets are predictable, and understanding them will help you build a realistic pro forma.
Your largest upfront line items will typically be:
- Buildout and equipment: Infusion chairs or recliners, IV poles, infusion pumps, vital sign monitors, a crash cart with resuscitation supplies, and the construction or renovation of clinical space including a pharmacy cleanroom if you plan to mix drugs on-site.
- Pharmacy cleanroom compliance: If your center will compound or reconstitute hazardous or non-hazardous drugs, you need rooms that meet United States Pharmacopeia (USP) chapter 797 and 800 standards. One study estimated ongoing operational costs for a 30-chair clinic maintaining USP-compliant cleanrooms for both hazardous and non-hazardous drugs, giving you a sense of the scale involved.3PubMed. Costs associated with United States pharmacopeia compliant infusion clinics These rooms require specialized HVAC systems, air handling, regular environmental monitoring, and periodic recertification.
- Health IT systems: Electronic medical records, infusion management software, scheduling tools, and pharmacy workflow technology. Some centers integrate their IV room workflow system directly with the EMR, which requires upfront implementation work but can improve efficiency and reduce errors down the line.4American Journal of Health-System Pharmacy. Implementation and evaluation of an IV room technology-assisted workflow system integrated within the electronic medical record at oncology infusion center pharmacies
- Initial drug inventory: Many infused therapies cost thousands of dollars per dose. You will need working capital to purchase drug inventory before you begin collecting reimbursement, which can take 30 to 90 days depending on the payer.
- Licensing, legal, and consulting fees: State licensure applications, DEA registration if you handle controlled substances, malpractice insurance, and potentially Certificate of Need filings.
A common mistake is underestimating pharmacy infrastructure costs. Some multisite practices have found that centralizing drug mixing at a single USP 797/800-compliant site, rather than building cleanrooms at every location, can reduce costs and improve quality by limiting the number of staff who prepare chemotherapy.5Journal of Clinical Oncology. Centralizing mixing of infusion drugs: A process to comply with USP 797/800, improve efficiency, and reduce costs in a multisite oncology infusion practice That approach also reduced training time for infusion nurses by about six weeks in one practice’s experience, because nurses no longer needed to learn drug preparation procedures.
Licensing and Certificate of Need Laws
Every state requires some form of clinical licensure for an infusion center, but the specific requirements vary widely. At a minimum, you will need a state health facility license, a pharmacy license if drugs are stored or prepared on-site, and compliance with federal CLIA regulations if any lab testing is performed. Many states also require registration with the state board of pharmacy and adherence to state-specific nursing scope-of-practice rules.
The bigger regulatory wildcard is whether your state has Certificate of Need (CON) laws. Roughly 35 states and the District of Columbia maintain some form of CON program, which requires healthcare providers to obtain state approval before opening new facilities or expanding services. The intent is to prevent oversaturation and control costs, but the evidence on whether CON laws actually achieve those goals is mixed. A systematic review found that CON regulations, on average, tend to increase health expenditures and overall elderly mortality, while reducing mortality specifically from heart surgery.6PubMed Central. Certificate of need laws: a systematic review and cost-effectiveness analysis The practical takeaway for you is straightforward: if your state has CON requirements that apply to ambulatory infusion, plan for a lengthy and potentially expensive application process. CON reviews can take months, require detailed market analyses, and may face opposition from existing providers who argue the area does not need additional capacity.
Whether or not your state has CON, you should also check for any local zoning restrictions, Americans with Disabilities Act compliance requirements for your physical space, and fire code rules around the storage of hazardous medications or medical gases like oxygen.
Designing the Physical Space
Infusion center layout is not just an aesthetic decision; it directly affects patient satisfaction, nurse efficiency, and clinical safety. The two dominant design philosophies are open-bay layouts, where patients sit in a large shared room, and pod-based or semi-private layouts, where patients are grouped in smaller clusters with partial walls or curtains.
Research comparing these approaches has found meaningful differences. A study evaluating a cancer infusion center’s transition to a pod-based design found that the new layout improved audio and visual privacy for patients, provided more work surface area and workstation availability for staff, reduced noise levels, and enhanced nurse concentration.7PubMed. Design of a Cancer Infusion Center: Results from a Pre- and Post-Occupancy Evaluation A separate study comparing traditional open-bay and semi-private infusion center designs examined the impact on nurses’ operational workflow and both nurse and patient satisfaction.8PubMed. The Impact of Infusion Center Layout on Workflow and Satisfactions in Two Cancer Infusion Centers: A Case Study on Staff and Patients
The tradeoff is that semi-private designs use more square footage per chair, which increases your real estate costs. Open-bay layouts allow nurses to visually monitor more patients simultaneously, which can be an advantage for safety. Many newer centers try to split the difference with a hybrid approach: semi-private bays for longer infusions where patients value privacy and comfort, and a few open-bay stations for quick injections or short treatments.
Regardless of layout, certain design elements are non-negotiable. You need clear sightlines from nursing stations to patient chairs, easy access to emergency equipment, adequate storage for drugs and supplies, handwashing stations within arm’s reach, and enough electrical outlets and data connections at each chair for infusion pumps and monitoring devices. Natural light and views of the outdoors are also consistently linked to better patient experience in healthcare design research, and they cost nothing extra if you plan for them during site selection.
Staffing an Infusion Center
Staffing is where many new infusion centers get their projections wrong, usually by underestimating how much nursing time each patient actually requires. A study analyzing nursing workload in hematology-oncology infusion settings found that the average nursing time per patient was about 1.4 hours, with roughly two-thirds of that being face-to-face time. Patients receiving anti-cancer therapies needed about 1.4 hours of nursing time on average, compared to 0.9 hours for patients receiving non-cancer therapeutic infusions. The average number of patient encounters per nursing full-time equivalent was 5.7, but the range was wide, from 1.5 to 11 encounters per nurse per day.9JCO Oncology Practice. Rethinking infusion staffing metrics to address the complexity of modern hematology-oncology therapies
That wide range is the key detail. Staffing based purely on patient headcount can be dangerously misleading. The same study found that nursing leaders reported increased cognitive load and burnout when staffing was based solely on patient counts, especially on days heavy with higher-acuity therapies or newer, more complex treatment regimens. A day with six patients on straightforward hydration therapy is nothing like a day with six patients on novel immunotherapies that require close monitoring for adverse reactions.
Beyond registered nurses, you will likely need a pharmacist (especially if you are doing on-site drug preparation), medical assistants or patient care technicians, a scheduling coordinator, and at least one financial coordinator to manage prior authorizations and insurance verification. Physician or advanced practice provider oversight is also required, though the level of on-site presence varies by state and payer.
Physician Supervision Requirements
Medicare’s rules around physician supervision are a frequent source of confusion, and they differ depending on whether your center is classified as a hospital outpatient department or a freestanding office. Under the Hospital Outpatient Prospective Payment System, most infusion services require “direct supervision,” meaning a physician must be immediately available on the premises to intervene if needed, though not necessarily in the room during the infusion. Freestanding physician offices follow the Physician Fee Schedule, which has its own set of supervision requirements.
Rural areas face a particular challenge. Only about 7% of oncologists practice in rural settings, even though roughly 19% of the U.S. population lives there.1PubMed Central. Supervision Requirements in the 2020 Hospital Outpatient Prospective Payment System: Implications for Cancer Care in the United States This mismatch has driven interest in telehealth-based supervision models, where a physician oversees infusion services remotely via video link. CMS has periodically adjusted its supervision rules, including temporary expansions during the COVID-19 public health emergency, some of which have been made permanent or extended. If you are planning a center in a rural or underserved area, check the most current CMS guidance on telehealth supervision, as the rules are still evolving.
Payer Contracting and Prior Authorization
Your infusion center lives or dies on payer contracts. The reimbursement rate you negotiate with each insurance company determines whether a given drug and administration service is profitable or money-losing at your site. Hospital outpatient rates are typically higher than freestanding rates for the same service, which is one reason some physician groups pursue provider-based billing arrangements when possible. But payers are increasingly scrutinizing site-of-care decisions and steering patients toward lower-cost settings, so the landscape is shifting.
Prior authorization is the other major revenue bottleneck. Many infused therapies, especially biologics and specialty drugs, require prior authorization from the payer before treatment can begin. Mismanaging this process leads to claim denials, treatment delays, and significant revenue loss. One health system’s experience illustrates the stakes: after centralizing its prior authorization services across two community hospital-based infusion clinics by deploying dedicated financial coordinators, denials related to the authorization workflow dropped by 68%, saving roughly $1.4 million. Total initial denials fell by 50%, resulting in overall cost savings of $3.8 million.10American Journal of Health-System Pharmacy. Centralization of prior authorization services at a community health system’s infusion clinics
The lesson is that investing in a dedicated financial coordination team upfront, rather than leaving prior authorization to clinical staff as a side task, pays for itself many times over. Your financial coordinators should verify benefits, obtain prior authorizations, track approval expiration dates, and handle initial denial appeals before they snowball.
Billing, Coding, and Drug Reimbursement
Infusion billing is more complex than standard office visit billing because you are billing for two distinct components on almost every claim: the drug itself and the administration service. Drugs are typically billed using J-codes, which are part of the HCPCS Level II coding system. Each J-code identifies a specific drug and dosage unit. These J-codes are paired with CPT codes that represent the administration service, such as the initial hour of IV infusion, each additional hour, or a subcutaneous injection. Together, these codes give the payer the full picture for claims processing.11careviso. What Is a J-Code in Medical Billing?
Getting this right requires trained billing staff who understand the nuances. Common errors include billing the wrong number of administration units (infusion time must be documented precisely), failing to bill for hydration or anti-emetic drugs administered alongside the primary therapy, and miscoding the drug quantity. Medicare reimburses most Part B drugs at the average sales price (ASP) plus a percentage markup, which means your acquisition cost relative to ASP determines your margin. Commercial payers may reimburse differently, and some negotiate rates as a percentage of wholesale acquisition cost instead.
Drug waste is another billing consideration. If a vial contains more drug than a patient’s dose requires, the unused portion may be billable under certain payer rules, but documentation requirements are strict. CMS requires the JW modifier to report discarded drug, and failing to use it correctly can trigger audits.
Emergency Preparedness and Infusion Reactions
Infusion reactions range from mild flushing and chills to life-threatening anaphylaxis, and they can occur unpredictably even after preventive measures like premedication. Your center needs written protocols, trained staff, and the right equipment in place before you see your first patient. Standing orders should allow nurses to intervene immediately if a reaction occurs, without waiting for a physician to arrive and write an order in real time.12The Oncologist. Management and Preparedness for Infusion and Hypersensitivity Reactions A crash cart should be readily accessible and stocked with epinephrine, bronchodilators, oxygen, a defibrillator, and other resuscitation equipment.
The standard response protocol for a suspected serious reaction involves stopping the infusion, triggering the emergency response chain, administering corticosteroids and antihistamines as indicated, and arranging for hospital transfer if the patient does not stabilize.13PubMed Central. The Healthcare Professionals’ Perspective on Impact and Actions Taken Following Severe Infusion Reaction Events in Oncology Centers in Europe Your proximity to an emergency department matters here. Freestanding centers that are far from a hospital need more robust on-site emergency capabilities, and some states set minimum standards for this.
Standardizing reaction management across your staff is important because the evidence emphasizes that prompt recognition and grading of reaction severity is what determines outcomes. A recent review highlighted the need for institutions to develop consistent protocols for monitoring patients at infusion initiation and escalating care based on severity.14PubMed Central. Management of infusion-related reactions in cancer therapy: strategies and challenges Regular simulation drills where staff practice responding to a mock anaphylaxis event are standard practice at well-run centers.
Tracking Operational Performance
Once your center is running, a few key metrics tell you whether it is operating efficiently or bleeding money. Chair utilization rate is the most watched number. According to a 2019 industry survey, the median daily scheduled chair utilization rate across infusion centers was 80%, while the median actual utilization rate (accounting for no-shows, cancellations, and scheduling gaps) was 70%.15Journal of Infusion Nursing / National Home Infusion Association. Development of Productivity Standards for Ambulatory Infusion Suite Nurses Within a Multi-Entity Health System Perhaps more striking, an earlier benchmark study found that infusion chairs were used for active treatment only 18% of total available chair time, meaning that most chair time is consumed by turnover, preparation, and idle periods.
That gap between scheduled and actual utilization is where operational improvement lives. Common strategies include staggering appointment start times to smooth the morning surge when most patients prefer to arrive, overbooking slightly based on historical no-show rates, and batching shorter treatments (injections, hydration) into time slots that would otherwise go unused between longer infusions. Template-based scheduling, where each chair has a daily template assigning blocks to short, medium, and long appointments, tends to outperform first-come-first-served approaches.
Beyond chair utilization, you should track nurse-to-patient ratios by acuity level, average wait time from scheduled appointment to infusion start, first-pass clean claim rate (what percentage of claims are accepted without rework), denial rate by payer, and drug waste as a percentage of total drug spend. These numbers, monitored monthly, will surface problems before they become crises.
Patient Financial Navigation
Many patients receiving infusion therapy face significant out-of-pocket costs, even with insurance. High-deductible health plans, specialty drug copays, and coinsurance requirements can create bills of hundreds or thousands of dollars per treatment cycle. If patients cannot afford their share, they skip treatments, which harms outcomes and also harms your center’s revenue when scheduled appointments become no-shows.
Building a financial navigation program into your operations from the start is both a patient care decision and a business decision. Multiple copay assistance foundations exist specifically to help patients receiving intravenous therapies. One oncology practice described a coordinated program with foundations including HealthWell, CancerCare, Patient Access Network, and the Chronic Disease Fund, among others, where patients requesting copay assistance were enrolled and their income, regimen, and copay information were submitted to determine eligibility for monetary support.16PubMed Central. A copay foundation assistance support program for patients receiving intravenous cancer therapy Drug manufacturers also frequently offer patient assistance programs for their branded therapies, and a financial coordinator who knows these programs well can recover significant revenue that would otherwise be lost to patient inability to pay.
Conducting a Market Analysis Before You Commit
Before signing a lease, you need to understand the demand picture in your target geography. How many patients in the service area are currently receiving infused therapies, and where are they going? What is the payer mix: heavily Medicare, heavily commercial, a mix? Are existing providers at capacity, or is there excess supply? These questions determine whether your center will fill its chairs or struggle to attract volume.
Larger health systems use formal planning tools to project infusion growth over five- and ten-year horizons, factoring in local demographics like age and sex distribution, disease prevalence, payer breakdown, and referral patterns.17PubMed Central. Navigating Access and Optimizing Medication Infusions in an Academic Medical Center: A Quality Improvement Study Smaller operators may not have access to the same sophisticated modeling, but you can still assemble a useful picture by reviewing local census data, disease prevalence estimates from public health departments, and the number and capacity of existing infusion sites in the area. Talking to local referring physicians about their unmet infusion needs is often more informative than any spreadsheet.
Payer mix is especially critical. A center in an area with a high proportion of Medicare Advantage patients may face aggressive prior authorization requirements and lower reimbursement than one serving primarily commercial PPO patients. Conversely, a center heavily dependent on a single large commercial payer is vulnerable if that payer changes its site-of-care policy or contracts with a competing provider. Diversifying your payer mix, your referral sources, and the types of therapies you offer (oncology, autoimmune, neurology, infectious disease) all reduce the risk that any single change wipes out your business model.